Aftab is a Managing Partner at Ajax Health. He additionally serves as Chairman of Summus Global and on the Board of Visitors of Duke University School of Medicine.

Prior to Ajax, Aftab was a Partner at Aisling Capital, a life science-dedicated investment fund in New York, where he continues to serve as an Operating Partner. While at Aisling, Aftab was actively involved with all aspects of sourcing, diligence, and managing investments in several private and public medtech, biopharma, and diagnostic companies. His historic board involvement includes companies such as Arcus Biosciences (NYSE:RCUS), Loxo Oncology (acquired by Eli Lilly), Spirox (acquired by Entellus), Syros Pharmaceuticals (NASDAQ:SYRS), and TransEnterix (NYSE:TRXC). Prior to Aisling, Aftab was an Engagement Manager at McKinsey & Company, where he was a member of the Pharmaceutical, Medical Product, and Private Equity practices. Before that, Aftab was a Chief Resident in Surgery at Duke University Medical Center, where he completed his residency in general surgery. He also completed a two-year post-doctoral research fellowship investigating treatments for heart failure, valve disease, and arrhythmia at Columbia University, College of Physicians & Surgeons. While at Columbia, he served as an organ procurement fellow as part of the cardiothoracic transplantation team of New York Presbyterian Hospital.

Aftab received his M.D. from Duke University School of Medicine, where he was a Howard Hughes Medical Institute Research Fellowship recipient, and his B.S. in Biology and A.B. in Economics from Duke University, awarded magna cum laude and graduating Phi Beta Kappa.

Brian serves as CEO of Thoracent, a Maverix company.

Brian founded Thoracent in 2017. Before that, he played a key role in launching and scaling the commercialization team at EndoChoice, a medtech startup. Over six years, he helped grow EndoChoice from $0 in sales to a NYSE-listed organization (NYSE: GI) with over $85 million in annual sales.

During his thirty-year career in medtech, Brian has also held sales positions at ev3, Boston Scientific, and Pfizer.

Brian holds a B.A. in Marketing from Siena College, where he was also a member of the football team.

Carla serves as Chief Commercial Officer of Maverix. She is also an Entrepreneur in Residence at Ajax Health.

Carla joined Maverix with 24 years of medtech experience at two of the industry’s top companies. Her last thirteen years were at Medtronic, building, transforming, and leading large sales organizations. Carla has successfully launched over ten products across the cardiovascular space, including electrophysiology, structural heart, and interventional cardiology.

Before Medtronic, Carla spent eleven years in sales at Boston Scientific as a commercial leader and director of the EP Fellows Program Division. She began her career in the Women’s Health division at Eli Lilly. Throughout her career, she has earned multiple distinguished awards for leadership, including the 2021 Wallin Award for strong performance and leadership as well as the GIDE Award for Inclusive Leadership.

Carla holds an M.B.A. from Columbia University and a B.A. from Villanova University.

David serves as Chief Operating Officer at Maverix. He is also a Partner at Ajax Health.

Prior to these roles, David was an associate at Latham & Watkins LLP, where he advised emerging companies and VC and PE firms on corporate governance issues, equity financings, and M&A transactions. Before Latham, David served as a judicial law clerk to Chief Justice John Roberts (U.S. Supreme Court), Judge Brett Kavanaugh (U.S. Court of Appeals), and Judge Dabney Friedrich (U.S. District Court), and as a judicial extern to Judge Mark Wallace (U.S. Bankruptcy Court).

David received his J.D. from Harvard Law School, where he served as editor of the Harvard Law Review and graduated first in his class, summa cum laude. He received his B.S., summa cum laude, from the University of Southern California. Before law school, David led business development for The Drop Box, a documentary film that has raised over $10 million for children with disabilities through strategic partnerships and worldwide distribution.

David serves as CEO of Diagnostics at Maverix.

David is also co-founder, Chairman, and President of the International Genomics Consortium (IGC), leading it to become the Biospecimen Core Resource and Tissue Source Site network for The Cancer Genome Atlas program.

Prior to Maverix, David was co-founder and President of Cirrus Bio, which was acquired by Maverix. Prior to Cirrus, he was the co-founder and President of Paradigm Diagnostics, Viomics, and the Molecular Profiling Institute, leading the companies through their acquisition and expansion by Exact Sciences and Caris Life Sciences. He helped develop and commercialize the first comprehensive, evidence-based personalized molecular and genomic assay in oncology in the United States and helped discover and commercialize blood-based screening targets to catch cancer early.

David received a B.A. in Human Biology and Studio Art from Stanford University and a J.D. and an M.B.A. from the University of Colorado at Boulder. He is a member of the Council on Foreign Relations, YPO, and the Colorado Bar Association.

Doug serves as CFO of Maverix. He also serves as Managing Partner at Ajax Health. He has over 25 years of experience in management consulting and as an executive of venture-backed companies.

Doug also served as CFO of Ajax company Cortex (acquired by Boston Scientific). Prior to these roles, Doug was the CFO of EPIX Therapeutics, which was acquired by Medtronic in 2019, the CFO of Spirox, which was acquired by Entellus in 2017, and the CFO of CV Ingenuity, which was acquired by Covidien in 2013. Prior to CV Ingenuity, Doug served as CFO and CEO at several high-tech and healthcare services companies. Doug began his professional career as a management consultant at Gemini Consulting.

Doug received an M.B.A. from Stanford University and a B.A. from UC San Diego.

Duke serves as Executive Chair at Maverix. Duke is also CEO and Managing Partner at Ajax Health.

Duke also served as CEO of Ajax company Cortex (acquired by Boston Scientific). Prior to these roles, Duke co-founded and served as the Chairman and CEO of EPIX Therapeutics, which was acquired by Medtronic in 2019. Prior to EPIX, Duke served as co-founder and CEO of Spirox, which was acquired by Entellus in 2017. Prior to Spirox, he co-founded and served as CEO of CV Ingenuity, which was acquired by Covidien in 2013. Prior to CV Ingenuity, Duke served in a variety of roles at FoxHollow Technologies before being named President. In this role, Duke led the sale of the company to ev3 (now Medtronic) in 2008. Prior to FoxHollow, Duke served as an Entrepreneur-in-Residence at the private equity firm Alta Partners. Duke began his professional career as the co-founder and President of a 9-unit, ~$20 million per year restaurant company. Duke currently serves on the Board of Directors of the Stanford University Athletic Department and as a Trustee of the United States Ski and Snowboard Association.

Duke received an M.B.A. from Harvard Business School and a B.A. from Stanford University.

Jeremy serves as Chief Medical Officer at Maverix. He is also Partner and SVP Medical at Ajax Health.

Jeremy is a practicing Interventional Radiologist and former Vice-Chair of Radiology at Memorial Sloan Kettering Cancer Center in New York. He is a past chair of the Society of Interventional Radiology Foundation and is a fellow of the American College of Radiology and Society of Interventional Radiology. Jeremy’s clinical experience is broad, ranging from image-guided endovascular, trauma, and biliary/GI/GU to oncologic interventions, with particular expertise in thoracic, genitourinary and venous procedures. Throughout his medical career, he has engaged in international clinical and scientific collaborations and remains active in clinical research. Jeremy has led multicenter and international clinical trials/registries and served as chair of numerous societal or institutional IT/informatics, quality and research committees.

Jeremy received a B.S. with distinction from Duke University in psychology and neuroscience, and his medical degree from the Stanford University School of Medicine. He completed a masters program in Biological and Medical Informatics at the University of California, San Francisco and is board-certified in radiology and medical informatics. Jeremy completed his Radiology residency and fellowship in Interventional Radiology at UCSF before joining the faculty. He is a recipient of National Science Foundation graduate fellowship, National Institute of Biomedical Imaging and Bioengineering T32, Prostate Cancer Foundation, Radiological Society of North America Roentgen, and Fulbright Specialist research awards.

Jocelyn serves as VP of Finance at Maverix. She is also Partner and SVP Finance at Ajax Health.

Jocelyn also served as VP of Finance at Ajax company Cortex (acquired by Boston Scientific). Prior to these roles, Jocelyn was the CFO of Symic Bio, a biopharmaceutical company that developed therapeutics focused on matrix biology. At Symic, Jocelyn was responsible for the management of all finance and accounting functions, as well as investor communication. Jocelyn was with Symic Bio from its inception to partnering of its lead assets. Jocelyn was also the CFO of TauTona Group, an early-stage life science venture. She was closely involved in the sale of TauTona’s assets to Allergan (AGN), LifeCell, and Novadaq (NVDQ). Previously, she was the Controller of CV Ingenuity, a medical device company that developed drug-coated balloon platforms that was acquired by Covidien. Jocelyn started her career at Deloitte and Touche, LLP, where she spent time in both the tax and audit departments.

Jocelyn received a B.A. from the University of San Diego.

Katherine serves as an Analyst at Maverix.

Katherine joined Maverix after graduating from the University of Southern California, where she received her B.S. in Finance and Biotechnology with honors. Katherine has also conducted pancreatic cancer research at the Salk Institute and currently sits on the board of a nonprofit focused on epidemic prevention.

Neil serves as VP of Research and Development at Maverix. He is also VP of Engineering at Ajax Health.

Neil brings 15 years of medtech R&D and Therapy Development experience in both startups and major strategics. Prior to these roles, he was Vice President of R&D at Half Moon Medical, incubated at The Foundry. Before that he was Principal R&D Engineer at Twelve, which was acquired by Medtronic, where he drove design of next-generation devices. Neil began his career at Edwards Lifesciences developing multiple new therapies from concept to the clinic as part of the Advanced Technology division.

Neil holds an M.S. in Mechanical Engineering from Stanford University and a B.S. in Biological Engineering from the Massachusetts Institute of Technology, where he earned Tau Beta Pi honors and served as captain of the soccer team.

Rebecca serves as CFO of Thoracent, a Maverix company.

Prior to Thoracent, Rebecca founded a management consulting firm to assist small businesses with corporate and financial management. Before consulting, Rebecca was a Senior Asset Manager at Colony Capital and a Vice President at various regional banks, where she analyzed the financial performance and cash flow projections of businesses.

Rebecca received a B.A in Economics from North Dakota State University, a certificate from the Graduate School of Banking at Colorado, and an M.B.A. from Loyola Marymount University, with an emphasis in Entrepreneurship. Rebecca’s research relating to the field of entrepreneurship has been published in academic journals. She serves as an Economic Development Commissioner for the City of Lakeville, MN.

Scott serves as Chief Science Officer for Diagnostics at Maverix.

Prior to Maverix, Scott was co-founder of Cirrus Bio and Chief Scientific Officer of the International Genomics Consortium (IGC), where he led the biospecimen core laboratory for The Cancer Genome Atlas project. Prior to Cirrus, he was co-founder and Chief Scientific Officer at Paradigm, where he built a flagship PCDx diagnostic, and co-founder and Chief Science Officer at Viomics, where he developed an AI naïve-bias algorithm for biomarker discovery and discovered a new class of biomarkers. Both companies were acquired by Exact Sciences, where Scott then led next-generation sequencing bioinformatics and multi-omics R&D as a Vice President and conducted primary scientific diligence for more than $3 billion in acquisitions, including Thrive and Base Genomics.

Scott received a B.S. in molecular biology and biotechnology, a P.S.M. in computational biology, a Ph.D. in industrial engineering, and an executive M.B.A. from Arizona State University.

Will serves as Director of Marketing and Communications at Maverix. He is also Chief of Staff at Ajax Health.

Will also served as Director of Marketing and Communications at Ajax company Cortex (acquired by Boston Scientific). Prior to these roles, Will was a tenured professor, who held positions at the University of Cambridge, the University of Oxford, Whitworth University, and Samford University. He is an award-winning author and teacher who has published seven books, including two with Oxford University Press, and thirty articles and book chapters.

Will received a Ph.D. from the University of Cambridge, an M.Litt. with distinction from the University of St. Andrews, and a B.A. with distinction from the University of Virginia.